Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

Registrieren

EWTX Edgewise Therapeutics Inc

18,33

-1,67 (-8,35%)

Nach Börsenschluss

Zuletzt aktualisiert: 22:00:35

Verzögert um 15 Minuten

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

null

Edgewise Therapeutics (NASDAQ:EWTX)
Historical Stock Chart
Von Apr 2024 bis Mai 2024

Click Here for more Edgewise Therapeutics Charts.

Edgewise Therapeutics (NASDAQ:EWTX)
Historical Stock Chart
Von Mai 2023 bis Mai 2024

Click Here for more Edgewise Therapeutics Charts.

News Edgewise Therapeutics Inc

Form 8-K - Current report
Freitag 10 Mai 2024 (8 Stunden vor) • Edgar (US Regulatory)

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers
Freitag 10 Mai 2024 (8 Stunden vor) • Edgar (US Regulatory)

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024
Freitag 10 Mai 2024 (9 Stunden vor) • Business Wire

Form S-8 - Securities to be offered to employees in employee benefit plans
Donnerstag 9 Mai 2024 (1 Tag vor) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Donnerstag 9 Mai 2024 (1 Tag vor) • Edgar (US Regulatory)

Form 8-K - Current report
Donnerstag 9 Mai 2024 (1 Tag vor) • Edgar (US Regulatory)

Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Donnerstag 9 Mai 2024 (1 Tag vor) • Business Wire

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Dienstag 7 Mai 2024 (3 Tage vor) • Edgar (US Regulatory)

Form 8-K - Current report
Dienstag 7 Mai 2024 (3 Tage vor) • Edgar (US Regulatory)

Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors
Dienstag 7 Mai 2024 (3 Tage vor) • Business Wire

Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)
Montag 6 Mai 2024 (4 Tage vor) • Business Wire

Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies
Dienstag 23 April 2024 (2 Wochen vor) • Business Wire

Weitere Edgewise Therapeutics Inc News-Artikel

Invesco QQQ Trust Series 1

Health Care Select Sector

Deutsche Telekom

JP Morgan Chase

Euro vs Sterling

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen